What's Hot
View all perspectives
TheDaoIndex KDAO2011
2 years 5 months ago
Another study that shows longterm exposure to pollutants can increased risk for autoimmune/immune mediated inflammatory diseases #EULAR2022 OP0071 @rheumnow #SaveEarth https://t.co/hMFJfEOcV1
David Liew drdavidliew
2 years 5 months ago
Once we add adalimumab in MTX-IR RA, can we dial down MTX & still keep control?
New data - now in East Asian pts (with already low MTX) says often yes, without ⬆️ADAb.
Obviously RA control 1st/2nd/3rd, but prob doesn’t have to be MTX 20 forever in everyone #EULAR2022 @RheumNow https://t.co/aZ0bsgY7dC
Dr. John Cush RheumNow
2 years 5 months ago
It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. #EULAR22 https://t.co/yYb0HaMWHJ
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
Prof Pickering explained interpretation of Low Complement level and its association with Complement Pathways and Diseases #EULAR2022 @RheumNow
💠 ⬇️C4, normal/⬇️C3: Classical
💠 ⬇️C3, normal C4: Alternative https://t.co/fBKKNzWnNW
David Liew drdavidliew
2 years 5 months ago
in case you're interesting in the causal diagram for the mediation modelling for this:
far from proven, but certainly does raise some questions about a potential advantage of IL-23 inhibitors in a crowded PsA market #EULAR2022 @RheumNow https://t.co/bSuE3tDHUO
Symplur Hashtags healthhashtags
2 years 5 months ago
Top Influencers of #EULAR2022: @eular_org @EMEUNET @RheumNow @ARD_BMJ @RichardPAConway @Yuz6Yusof @ProftDr More 📊 https://t.co/fUfohEZAoX
Richard Conway RichardPAConway
2 years 5 months ago
Interesting, NWA by Dougados et al shows both Tofa and ADA may benefit pain in those who have controlled inflammatory component. ?real effect vs imperfect measures @RheumNow #EULAR2022 OP0052 https://t.co/aYBTaSDa3v https://t.co/dkLv1l5tFy
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0263 #EULAR2022 In #rituximab-treated RMD patients with undetectable humoral response to primary #COVID 💉, a study (N=84) found Re-Vaccination with mRNA (2 shots) was better than a Booster (1 shot). Lend support for current approach: 2 + 3rd Primary + Booster @RheumNow https://t.co/AH0wpVKbHc
Richard Conway RichardPAConway
2 years 5 months ago
Burja et al. Dimethyl alpha-ketoglutarate has anti-inflammatory and anti-fibrotic effects on explanted systemic sclerosis skin. @RheumNow #EULAR2022 OP0095 https://t.co/PSbnVh6uta https://t.co/2ij9HgoU6Q
Dr. John Cush RheumNow
2 years 5 months ago
RheumNow Coverage of #EULAR2022 Presents Live Expert Discussions https://t.co/FeE0WfXw1z
Richard Conway RichardPAConway
2 years 5 months ago
Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria
⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️
⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️
⭐️Ankylosis much higher in ♂️ (DOR 40!)
@Rheumnow
Poster Hall